Athersys (NASDAQ:ATHX) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of Athersys (NASDAQ:ATHX) in a research note issued to investors on Friday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Athersys Price Performance

NASDAQ ATHX opened at $0.01 on Friday. The stock has a market capitalization of $370,314.00, a PE ratio of 0.00 and a beta of -0.90. The company has a 50 day moving average price of $0.01 and a two-hundred day moving average price of $0.05. Athersys has a 12-month low of $0.01 and a 12-month high of $1.99.

Institutional Trading of Athersys

A number of institutional investors and hedge funds have recently modified their holdings of ATHX. Private Advisor Group LLC acquired a new stake in shares of Athersys in the first quarter worth $27,000. BNP Paribas Arbitrage SA lifted its stake in shares of Athersys by 604.4% in the second quarter. BNP Paribas Arbitrage SA now owns 129,530 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 111,140 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new stake in shares of Athersys in the fourth quarter worth $36,000. CIBC Asset Management Inc acquired a new stake in shares of Athersys in the first quarter worth $45,000. Finally, Jane Street Group LLC lifted its stake in shares of Athersys by 438.1% in the second quarter. Jane Street Group LLC now owns 186,076 shares of the biopharmaceutical company’s stock worth $48,000 after buying an additional 151,494 shares during the last quarter. 19.35% of the stock is currently owned by institutional investors and hedge funds.

Athersys Company Profile

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.